Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Pharmacol Biochem Behav ; 177: 1-11, 2019 02.
Article in English | MEDLINE | ID: mdl-30582934

ABSTRACT

The neuroprotective effect of autophagy activation by rapamycin and trehalose was studied in a mouse model of Parkinson's disease (PD) induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Both rapamycin (10 mg/kg/day, 7 days) and trehalose (2% in drinking water, 7 days) increased the expression of LC3-II (a marker of autophagy activation) in the frontal cortex and striatum of normal C57Bl/6J mice, with signs of an additive effect. Autophagy stimulation in the striatum was confirmed by a lysosomal osmotic test. In the model of MPTP-induced PD, the two drugs were applied starting from the 2nd day after subchronic daily MPTP administration (20 mg/kg/day, 4 days). A marked increase in LC3-II expression in the striatum was detected under the action of trehalose and in the S. nigra after combined treatment with rapamycin and trehalose. The drugs had a positive effect for recovery of dopaminergic neurons and neuroprotection after MPTP-induced PD-like injury. The therapeutic effect was proven by active restoration of tyrosine hydroxylase (TH) content in the striatum and S. nigra and by improved cognition measured by the passive avoidance learning task. The results revealed the additive effect of the combined treatment with rapamycin and trehalose on dopaminergic deficits (according to the levels of TH expression in the nigrostriatal system) but not on the behavioral performance in the mouse PD model. Thus, the autophagy activation through different pathways by the combination of rapamycin and trehalose reverses both neuronal dopaminergic and behavioral deficits in vivo and seems to be a promising therapy for PD-like pathology.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Autophagy/drug effects , MPTP Poisoning/drug therapy , Neuroprotective Agents/therapeutic use , Neurotoxins/pharmacology , Sirolimus/therapeutic use , Trehalose/therapeutic use , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/administration & dosage , Animals , Behavior, Animal/drug effects , Cognition/drug effects , Corpus Striatum/metabolism , Disease Models, Animal , Dopamine/metabolism , Dopaminergic Neurons/drug effects , Drug Therapy, Combination , Male , Mice , Mice, Inbred C57BL , Microtubule-Associated Proteins/metabolism , Neurotoxins/administration & dosage , Parkinson Disease/drug therapy , Sirolimus/administration & dosage , Substantia Nigra/metabolism , Trehalose/administration & dosage , Tyrosine 3-Monooxygenase/metabolism
2.
J Cardiovasc Pharmacol ; 70(5): 339-352, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28777256

ABSTRACT

The poloxamer 407 (P-407) nongenetic, nondiet-induced mouse model of dose-controlled hyperlipidemia and atherosclerosis was first introduced in 1992. Dyslipidemia is produced in C57BL/6 mice of either sex after intraperitoneal administration of P-407 that is a polyether-based nonionic surface active agent. Aortic atherosclerotic lesions begin to form after 1 month of repeated P-407 administration and obtain maximum size, numerical density, and human-like pathological features by 4 months. Our laboratory published a review of this model in 2004, although an update would seem both appropriate and timely based on new findings since 2004. Using P-407-treated mice, we have investigated the effect that hyperlipidemia has on the activity of several classes of proteases in the heart, liver, and serum; extensively characterized lipoprotein fractions and subfractions associated with atherogenic plasma lipids; investigated whether several key vascular cell adhesion molecules were perturbed; and determined whether the biological activity of 2 peroxisome proliferator-activated receptors was modulated both in vitro and in vivo. Based on our findings since 2004, as well as those before 2004 (1992-2004), we would strongly suggest that the P-407-induced hyperlipidemic mouse model represents a convenient, inexpensive, and well-documented alternative mouse model with which to study cardiovascular heart disease arising from dyslipidemia and atherosclerosis.


Subject(s)
Atherosclerosis/chemically induced , Disease Models, Animal , Hyperlipidemias/chemically induced , Poloxamer/toxicity , Animals , Atherosclerosis/metabolism , Atherosclerosis/pathology , Dose-Response Relationship, Drug , Hyperlipidemias/metabolism , Hyperlipidemias/pathology , Lipid Peroxidation/drug effects , Lipid Peroxidation/physiology , Mice , Poloxamer/administration & dosage , Time Factors
3.
Lipids Health Dis ; 15: 16, 2016 Jan 22.
Article in English | MEDLINE | ID: mdl-26801626

ABSTRACT

BACKGROUND: The aims of this study were to evaluate the effect of poloxamer 407 administration on atherogenic serum lipoprotein fractions and subfractions associated with cholesterol, triglycerides and phospholipids, as well as the onset of early atherosclerosis, in mice. METHODS: Mice were administered either sterile saline or poloxamer 407 (to induce a dose-controlled hyperlipidemia) for 1 month and then sacrificed at 1, 4 and 10 days after the last dose of poloxamer 407. Systolic and diastolic blood pressure, the activity of a cysteine protease (cathepsin B) in cardiac and liver tissue, and histological/morphological examination of heart and liver specimens was performed for each group of mice at each time point. Lastly, small angle X-ray scattering was utilized to analyze the lipoprotein fractions and subfractions associated with cholesterol, triglycerides and phospholipids for both groups of mice at each time point. Statistical analysis was performed using one-way, analysis-of-variance with post hoc analysis to determine significantly different mean values, while correlation analysis employed the Spearman test. RESULTS: Poloxamer 407-treated mice revealed significant hyperlipidemia, moderately elevated blood pressure, general lipidosis in liver cells, increased cysteine protease activity in heart tissue, and contractile-type changes in cardiomyocytes. Similar to humans, the onset of atherosclerosis in poloxamer 407-treated mice was characterized by a steady increase in serum low-density, intermediate-density and very-low-density lipoprotein fractions, as well as very-low-density lipoprotein subfractions. CONCLUSIONS: We would propose that the sustained elevation of serum atherogenic lipoprotein fractions and subfractions induced by the administration of poloxamer 407 to mice resulted in the morphological changes we observed in both heart and liver cells, which are suggested to precede atherosclerosis, since this is a well-established mouse model of atherosclerosis. Since most of the cellular, biochemical and physiological changes documented in the present study using poloxamer 407-treated mice are related to the symptoms of early atherosclerosis in humans, it is suggested that the poloxamer 407-induced mouse model of hyperlipidemia and atherosclerosis might prove beneficial as an experimental animal model with which to evaluate the pathological features observed in early-stage atherosclerosis.


Subject(s)
Atherosclerosis/blood , Atherosclerosis/pathology , Hyperlipidemias/blood , Hyperlipidemias/pathology , Lipoproteins/blood , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Atherosclerosis/complications , Atherosclerosis/physiopathology , Blood Glucose/metabolism , Blood Pressure , Cathepsin B/metabolism , Diastole , Hyperlipidemias/complications , Hyperlipidemias/physiopathology , Intracellular Membranes/metabolism , Liver/enzymology , Liver/pathology , Lysosomes/metabolism , Male , Mice, Inbred CBA , Myocardium/enzymology , Myocardium/pathology , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Permeability , Poloxamer/administration & dosage , Systole , Time Factors
4.
Interdiscip Toxicol ; 6(1): 18-25, 2013 Mar.
Article in English | MEDLINE | ID: mdl-24170975

ABSTRACT

Chronic administration of the poloxamer 407 (P-407), a block copolymer, to elevate serum lipids in mice is a well-established mouse model of hyperlipidemia and atherosclerosis. We tested the hypothesis that the activity of several types of proteases in heart and liver tissue is changed in the early stages of atherosclerosis development. Additionally, we evaluated whether increased serum lipids would induce anxiety in mice, as determined by using a 'plus-maze' test. The mice were administered P-407 by intraperitoneal injection twice a week for one month. P-407 administration to mice resulted in a marked increase in total serum cholesterol, atherogenic non-HDL-cholesterol, and especially in total triglycerides, and it also increased anxiety. Morphological changes observed in P-407-treated mice included contractile type changes in cardiomyocytes and foamy macrophages in liver. A significant increase of cysteine proteases cathepsin B and cathepsin L (at 24 h) and aspartate protease cathepsin D (at both 24 h and 5 days) was determined in heart tissue following P-407 administration. However, no changes were noted in heart matrix metalloproteinase activity. The activity of cysteine and aspartate proteases was significantly increased in liver at both 24 hours and 5 days after P-407 administration. In conclusion, administration of P-407 to mice for one month resulted in increased anxiety, and more importantly, there was an increase in the activity of heart and liver proteases secondary to sustained dyslipidemia. It is suggested that heart and liver cysteine and aspartate proteases may represent potential therapeutic targets in the early stages of atherosclerosis.

5.
Article in English | MEDLINE | ID: mdl-23984285

ABSTRACT

OBJECTIVES: To investigate the possible role of cystatin C in eye biological fluids locally and in serum and lactoferrin revealing anti-tumor activity in eye tumor development. BACKGROUND: The increased number of eye tumors was registered recently not only in the countries with high insolation, but also in the northern countries including Russia (11 cases per million of population). Search for new biological markers is important for diagnosis and prognosis in eye tumors. Cystatin C, an endogenous inhibitor of cysteine proteases, plays an important protective role in several tumors. Lactoferrin was shown to express anti-tumor and antiviral activities. It was hypothesized that cystatin C and lactoferrin could serve as possible biomarkers in the diagnosis of malignant and benign eye tumors. STUDY DESIGN: A total of 54 patients with choroidal melanoma and benign eye tumors were examined (part of them undergoing surgical treatment). Serum, tear fluid and intraocular fluid samples obtained from the anterior chamber of eyes in patients with choroidal melanoma were studied. METHODS: Cystatin C concentration in serum and eye biological fluids was measured by commercial ELISA kits for human (BioVendor, Czechia); lactoferrin concentration--by Lactoferrin-strip D 4106 ELISA test systems (Vector-BEST, Novosibirsk Region, Russia). RESULTS: Cystatin C concentration in serum of healthy persons was significantly higher as compared to tear and intraocular fluids. In patients with choroidal melanoma, increased cystatin C concentration was similar in tear fluid of both the eyes. Lactoferrin level in tear fluid of healthy persons was significantly higher than its serum level. Significantly increased lactoferrin concentration in tear fluid was noted in patients with benign and malignant eye tumors. CONCLUSION: Increased level of cystatin C in tear fluid seems to be a possible diagnostic factor in the eye tumors studied. However, it does not allow us to differentiate between malignant and benign eye tumors. Similar changes were noted for lactoferrin in tear fluid.


Subject(s)
Cystatin C/analysis , Eye Neoplasms/diagnosis , Lactoferrin/analysis , Adult , Aged , Aged, 80 and over , Aqueous Humor/chemistry , Biomarkers/analysis , Biomarkers/blood , Case-Control Studies , Choroid Neoplasms/blood , Choroid Neoplasms/diagnosis , Cystatin C/blood , Eye Neoplasms/blood , Female , Humans , Lactoferrin/blood , Male , Melanoma/blood , Melanoma/diagnosis , Middle Aged , Tears/chemistry
6.
Article in English | MEDLINE | ID: mdl-23986888

ABSTRACT

OBJECTIVES: To evaluate procathepsin B, as well as endogenous inhibitors of cysteine proteases (cystatin B and cystatin C) in biological fluids as possible biomarkers of ovarian cancer. To observe levels of serum procathepsin B in different age groups. STUDY DESIGN: The sample (N=27) of women with gynaecological tumours included 18 patients with ovarian cancer (n=18) and 9 patients with benign ovarian tumours (n=9); 72 healthy women were in the control group. All patients were treated in Novosibirsk Regional Oncological Center, Russia. Serum samples of healthy women (n=40) aged 18-70 years were used as controls for common biomarker of ovarian cancer CA-125. In the Procathepsin B study, serum samples of healthy women (n=32) aged 18-40 years (n=14), 41-55 years (n=10) and 56-80 (n=8) years were used as controls. METHODS: Common biomarker of ovarian cancer, CA-125, was assayed by using a commercial kit (Vector, Koltsovo, Novosibirsk Region, Russia). Procathepsin B was measured by means of a commercial kit for human procathepsin B (R&D, USA); cystatin C was measured by commercial ELISA kits for human (BioVendor, Czechia); cystatin B was measured by ELISA kits for human (USCN Life Science Inc., Wuhan, China). Statistical analysis was performed by one-way ANOVA (Statistica 10 Program). RESULTS: In the control group, serum procathepsin B concentration did not reveal age dependency. In the ovarian cancer group, both levels of serum procathepsin B and standard biomarker CA-125 increased significantly (both p<0.001) compared with the control group. In the benign ovarian tumour group, serum procathepsin B (p<0.001) and CA-125 (p=0.004) increased about 2.5- and 8-fold compared to the control group. Serum cystatin B level increased up to 1.7-fold in the ovarian cancer group compared to the control group. The increase of serum CA-125 was about 3.5-fold higher (p=0.017) and procathepsin B was 1.8-fold higher (p<0.05) in the ovarian cancer group compared to the benign tumour group. Cystatin B in ascites fluid increased equally in both ovarian cancer (p<0.001) and benign ovarian tumours group (p<0.05). Cystatin C concentration in ascites fluid increased only in patients with ovarian cancer (p<0.05) and did not change in the benign tumours group. Large increases of procathepsin B level (about 13-fold, p<0.001) and to a lesser degree of cystatin C (1.8-fold, p<0.05) and cystatin B levels (1.4 fold, p<0.001) were revealed in ascites fluids of patients with ovarian cancer compared to the control serum. The significant difference in serum procathepsin B levels was noted between the ovarian cancer and benign tumour groups (p<0.05), which could be used in differential diagnostics between malignant and benign gynaecological tumours. CONCLUSION: Serum procathepsin B demonstrated significant promise as a new biomarker of ovarian cancer.


Subject(s)
Cathepsin B/blood , Cystatin B/blood , Cystatin C/blood , Enzyme Precursors/blood , Ovarian Neoplasms/blood , Adolescent , Adult , Age Factors , Aged , Biomarkers/blood , CA-125 Antigen/blood , Case-Control Studies , Female , Humans , Middle Aged , Ovarian Neoplasms/diagnosis , Young Adult
7.
Can J Physiol Pharmacol ; 90(11): 1456-68, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23181274

ABSTRACT

The effects of repeated administration of poloxamer 407 (P-407) on lipoprotein-cholesterol (LP-C) and lipoprotein-triglyceride (LP-TG) fractions and subfractions, as well as the effect on liver and heart proteases, were studied. Repeated administration of P-407 to male CBA mice resulted in a model of atherosclerosis with increased diastolic blood pressure; there was a drastic increase in total serum cholesterol and especially TG. A novel small-angle X-ray scattering method for the determination of the fractional and subfractional composition of LP-C and LP-TG was used. In chronically P-407-treated mice, P-407 significantly increased atherogenic low-density lipoprotein C (LDL-C) fractions, as well as intermediate-density lipoprotein C (IDL-C), and LDL1₋3-C subfractions, and very-low-density lipoprotein-C (VLDL-C) fractions, as well as VLDL1₋2-C and VLDL3₋5-C subfractions), to a lesser extent, the total anti-atherogenic high-density lipoprotein C (HDL-C) fraction, as well as HDL2-C and HDL3-C subfractions. Additionally, we demonstrated an increase in the serum chitotriosidase activity, without significant changes in serum matrix metalloprotease (MMP) activity. Morphological changes observed in P-407-treated mice included atherosclerosis in the heart and storage syndrome in the liver macrophages. P-407 significantly increased the activity of cysteine, aspartate proteases, and MMPs in the heart, and only the activity of cathepsin B and MMPs in the liver of mice. Thus, repeated administration of P-407 to mice induced atherosclerosis secondary to sustained dyslipidemia and formation of foamy macrophages in liver, and also modulated the activity of heart and liver proteases.


Subject(s)
Atherosclerosis/etiology , Disease Models, Animal , Dyslipidemias/chemically induced , Lipoproteins/blood , Liver/enzymology , Myocardium/enzymology , Animals , Atherosclerosis/immunology , Atherosclerosis/metabolism , Atherosclerosis/pathology , Cathepsins/metabolism , Cholesterol/blood , Dyslipidemias/physiopathology , Foam Cells/immunology , Foam Cells/ultrastructure , Hexosaminidases/blood , Hypertension/chemically induced , Hypertension/physiopathology , Lipoproteins, IDL/blood , Lipoproteins, VLDL/blood , Liver/immunology , Liver/ultrastructure , Male , Metalloproteases/metabolism , Mice , Mice, Inbred CBA , Myocardium/ultrastructure , Poloxamer , Triglycerides/blood
8.
Can J Physiol Pharmacol ; 90(2): 141-53, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22320860

ABSTRACT

The effects of atorvastatin and carboxymethylated ß-glucan (CMG) on the lipoprotein-cholesterol (LP-C) and lipoprotein-triglyceride (LP-TG) fractions and subfractions at the early stage of murine hyperlipidemia, and its pleiotropic anti-inflammatory effects, were studied. Atorvastatin and CMG were administered in ICR male mice with acute lipemia induced with a single injection of poloxamer 407 (P-407). A novel small-angle X-ray scattering method for the determination of fractional and subfractional composition of LP-C and LP-TG was used. In P-407-treated animals, there was a drastic increase of total cholesterol and especially TG. Atorvastatin decreased both the total cholesterol and TG, but not to control levels. CMG primarily decreased TG and was not as potent as atorvastatin. P-407 increased atherogenic LDL-C (IDL-C and LDL(1-3)-C subfractions) and very low-density lipoprotein-C (VLDL-C) (VLDL(1-2)-C and VLDL(3-5)-C subfractions) fractions, with an increase of the total anti-atherogenic HDL-C fraction (HDL(2)-C subfraction). Atorvastatin treatment of lipemia was followed by a decrease in the total LP-C, total LDL-C (LDL(1-3)-C subfraction), and the LDL(1-3)-TG subfraction. Additionally, atorvastatin treatment resulted in an increase in the serum matrix metalloproteases activity both in control and P-407-treated mice. In general, high-dose atorvastatin therapy exerts its lipid-lowering and pleiotropic effects in the early stages of acute lipemia induced in mice by treatment with P-407.


Subject(s)
Heptanoic Acids/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hyperlipidemias/drug therapy , Lipoproteins/blood , Matrix Metalloproteinases/blood , Poloxamer , Pyrroles/pharmacology , beta-Glucans/pharmacology , Animals , Atorvastatin , Biomarkers/blood , Cholesterol, LDL/blood , Disease Models, Animal , Hyperlipidemias/blood , Hyperlipidemias/chemically induced , Hyperlipidemias/enzymology , Lipoproteins, LDL/blood , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Mice , Mice, Inbred ICR , Scattering, Small Angle , Time Factors , Triglycerides/blood , X-Ray Diffraction
9.
J Pharm Pharmacol ; 63(6): 833-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21585382

ABSTRACT

OBJECTIVES: The effects of atorvastatin on the atherogenic and anti-atherogenic lipoprotein-cholesterol (C-LP) and lipoprotein-triglyceride (TG-LP) fractions and subfractions at the early stage of murine acute hyperlipidaemia, and its pleiotropic anti-inflammatory effects via the activity of matrix metalloproteinases (MMPs) were studied. METHODS: Atorvastatin (75 mg/kg) was administered to ICR mice with acute lipaemia induced by a single injection of Triton WR 1339 (500 mg/kg). A novel small-angle X-ray scattering (SAXS) method was used for the determination of the fractional and subfractional composition of C-LP and TG-LP. KEY FINDING: In Triton WR 1339-treated mice, there was a drastic increase in the atherogenic low-density C-LP (C-LDL) fraction, intermediate density lipoprotein-cholesterol (C-IDL) subfraction, and very low-density C-LP (C-VLDL) fractions (C-VLDL(3-5) subfraction). Additionally, there was an increase in the C-HDL(3) subfraction. Treatment of lipaemia with atorvastatin resulted in the normalization of the atherogenic C-LDL fraction and the C-IDL subfraction. A decrease in C-VLDL (C-VLDL(3-5) subfraction), total cholesterol and, especially, triglyceride (TG) concentrations was also demonstrated. Similar results were obtained with the TG-LP fractions and subfractions. Additionally, atorvastatin treatment resulted in an increase in the serum and liver MMP activity. CONCLUSION: High-dose atorvastatin therapy exerts its rapid lipid-lowering and pleiotropic effect(s) in the early stages of acute lipaemia induced with Triton WR-1339.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Cholesterol/blood , Heptanoic Acids/pharmacology , Hyperlipidemias/metabolism , Hypolipidemic Agents/pharmacology , Lipoproteins/blood , Matrix Metalloproteinases/metabolism , Pyrroles/pharmacology , Animals , Anti-Inflammatory Agents/therapeutic use , Atorvastatin , Heptanoic Acids/therapeutic use , Hyperlipidemias/chemically induced , Hyperlipidemias/drug therapy , Hypolipidemic Agents/therapeutic use , Liver/drug effects , Liver/metabolism , Male , Matrix Metalloproteinases/blood , Mice , Mice, Inbred ICR , Polyethylene Glycols , Pyrroles/therapeutic use , Scattering, Small Angle , Triglycerides/blood , X-Ray Diffraction/methods
10.
Int Immunopharmacol ; 9(6): 729-33, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19268718

ABSTRACT

By means of carboxymethylation, a novel water-soluble carboxymethyl chitin-glucan (CM-CG) was prepared from the mycelium of Aspergillus niger, and its ability to stimulate macrophages was assessed and compared to that of the previously studied carboxymethylated glucan (CMG) from the yeast Saccharomyces cerevisiae. It was demonstrated that single intraperitoneal (i.p.) administration of CMG and CM-CG to the CBA mice led to a significant increase of leukocyte number. At the same time, the number of monocytes in the bone marrow was increased to more than two-fold. Application of both polysaccharides also resulted in the augmented number of liver macrophages and to the rise of their content of the secondary lysosomes. A markedly enhanced carbon clearance was observed as well as the increased release of tumor necrosis factor-alpha by the peritoneal macrophages indicating their amplified phagocytic activity. The effect of CM-CG in these experiments was ca. 1.7 times higher than that of CMG. Administration of both polysaccharides also led to the elevated level of free acid phosphatase in liver homogenate, implying labilization of the lysosomes. Increased serum chitotriosidase also indicated increased macrophage activity. The results obtained indicate similar in vivo macrophage stimulation activity of both applied fungal polysaccharides and suggest their potential clinical use as non-toxic natural compounds.


Subject(s)
Adjuvants, Immunologic/pharmacology , Aspergillus niger/chemistry , Chitin/analogs & derivatives , Glucans/pharmacology , Macrophages/drug effects , Acid Phosphatase/immunology , Acid Phosphatase/metabolism , Adjuvants, Immunologic/chemistry , Adjuvants, Immunologic/isolation & purification , Animals , Aspergillus niger/immunology , Bone Marrow/drug effects , Bone Marrow/immunology , Chitin/chemistry , Chitin/isolation & purification , Chitin/pharmacology , Glucans/chemistry , Glucans/isolation & purification , Hexosaminidases/blood , Lysosomes/drug effects , Lysosomes/immunology , Macrophages/immunology , Male , Mice , Mice, Inbred CBA , Phagocytosis/drug effects , Phagocytosis/immunology , Saccharomyces cerevisiae/chemistry , Saccharomyces cerevisiae/immunology
11.
Cancer Lett ; 223(1): 77-83, 2005 Jun 01.
Article in English | MEDLINE | ID: mdl-15890239

ABSTRACT

Changes in the activity of cysteine (cathepsins B and L) and aspartyl (cathepsin D) proteases were investigated at the development of susceptible and resistant variants of murine lymphosarcoma (LS). It has been demonstrated that the variant resistant to the cyclophosphamide treatment is characterized by a lower activity of all three cathepsins in the tumor tissue. Application of a higher dose of cyclophosphamide led to a more pronounced increase of the studied enzymatic activity in mice with a resistant variant of LS, than in those with a susceptible one. Administration of a yeast polysaccharide derivative - sulfoethyl glucan - enhanced therapeutic effect of cyclophosphamide in mice with both variants of LS, while the most efficient dose was found to be that of 10mg/kg body mass. In the intact mice, usage of both cyclophosphamide and sulfoethyl glucan led to a similar increase of the cathepsins activity in liver and spleen.


Subject(s)
Cathepsin B/metabolism , Cathepsin D/metabolism , Cathepsins/metabolism , Cyclophosphamide/administration & dosage , Cysteine Endopeptidases/metabolism , Glucans/administration & dosage , Lymphoma, Non-Hodgkin/enzymology , Yeasts/chemistry , Animals , Cathepsin L , Lymphoma, Non-Hodgkin/drug therapy , Male , Mice , Mice, Inbred CBA , Mice, Inbred DBA
12.
Int Immunopharmacol ; 2(6): 775-81, 2002 May.
Article in English | MEDLINE | ID: mdl-12095168

ABSTRACT

The efficiency of chemotherapy of Lewis lung carcinoma with cyclophosphamide was affected by administration of the water-soluble yeast polysaccharide derivative--carboxymethylated (1 --> 3)-beta-D-glucan (CMG)-a well-known macrophage stimulator. It was found that while cyclophosphamide showed 57% growth inhibition of the intramuscular tumor implants in comparison with the control group, its combined administration with CMG led to 75-90% inhibition. Similarly, increased inhibition of occurrence of lung metastases (up to 92-94%) was observed using the combined application of the two compounds. The stimulatory effect of CMG is not associated with the changed cellularity of peripheral blood, but is rather due to the obviously increased concentration of the intracellular inhibitor of cysteine proteases-stefin A and cystatin C in tumor tissue.


Subject(s)
Carcinoma, Lewis Lung/drug therapy , Glucans/therapeutic use , Macrophages/metabolism , beta-Glucans , Animals , Carcinoma, Lewis Lung/enzymology , Carcinoma, Lewis Lung/metabolism , Cyclophosphamide/pharmacology , Cyclophosphamide/therapeutic use , Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/metabolism , Drug Therapy, Combination , Glucans/pharmacology , Leukocytes/cytology , Leukocytes/drug effects , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Lung Neoplasms/secondary , Macrophages/drug effects , Macrophages/enzymology , Male , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Saccharomyces cerevisiae/isolation & purification , Saccharomyces cerevisiae/metabolism , Xenograft Model Antitumor Assays/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...